Pulmonary toxicity after intraperitoneal mitomycin C: a case report of a rare complication of HIPEC.

Related Articles

Pulmonary toxicity after intraperitoneal mitomycin C: a case report of a rare complication of HIPEC.

World J Surg Oncol. 2017 Feb 20;15(1):49

Authors: Abel ML, Kokosis G, Blazer DG

Abstract
BACKGROUND: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has become a common treatment approach for disseminated appendiceal neoplasms. Systemic absorption of intraperitoneal chemotherapeutics may lead to drug-induced toxicity, most commonly neutropenia. Mitomycin C has been the most commonly used chemotherapeutic in HIPEC for the past several decades.
CASE PRESENTATION: Here, we describe a rare pulmonary complication secondary to intraperitoneal administration of mitomycin C.
CONCLUSIONS: While rare, intraperitoneal mitomycin C has the potential to cause serious pulmonary toxicity that should be considered with administration. To our knowledge, this report represents only the second case described in the literature.

PMID: 28219391 [PubMed - in process]

http://ift.tt/2mleTfX